Raymond James analyst Gary Nachman raised the firm’s price target on AbbVie (ABBV) to $250 from $236 and keeps an Outperform rating on the shares. AbbVie had “good” outperformance in Q3, driven largely by a greater focus on fundamentals, with strong Q2 results for key growth drivers and generic settlements extending Rinvoq’s exclusivity, the analyst tells investors in a research note. AbbVie should remain a core holding, the firm argues.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- 3 Best Dividend Aristocrat Stocks to Buy Now, 10/16/2025
- AbbVie’s Phase 2 Study on CLL/SLL Treatment: Key Updates and Market Impact
- AbbVie’s Venetoclax Study Completion: A Potential Boost for Investors
- Psychedelic: Needham initiates coverage of atai, GH Research, MindMed
- Enveric hires firm to contest post-grant review petition filed by Gilgamesh